An exploratory, open-label, randomized, multicenter trial of hachimijiogan for mild Alzheimer’s disease

Background: Alzheimer’s disease (AD) is a progressive neurodegeneration and is the most prevalent form of dementia. Intervention at an early stage is imperative. Although three acetylcholinesterase inhibitors (AChEIs) are currently approved for the treatment of mild AD, they are not sufficiently eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Kainuma, Mosaburo, Ouma, Shinji, Kawakatsu, Shinobu, Iritani, Osamu, Yamashita, Ken-Ichiro, Ohara, Tomoyuki, Hirano, Shigeki, Suda, Shiro, Hamano, Tadanori, Hieda, Sotaro, Yasui, Masaaki, Yoshiiwa, Aoi, Shiota, Seiji, Hironishi, Masaya, Wada-Isoe, Kenji, Sasabayashi, Daiki, Yamasaki, Sho, Murata, Masayuki, Funakoshi, Kouta, Hayashi, Kouji, Shirafuji, Norimichi, Sasaki, Hirohito, Kajimoto, Yoshinori, Mori, Yukiko, Suzuki, Michio, Ito, Hidefumi, Ono, Kenjiro, Tsuboi, Yoshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616163/
https://www.ncbi.nlm.nih.gov/pubmed/36313371
http://dx.doi.org/10.3389/fphar.2022.991982

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616163/
https://www.ncbi.nlm.nih.gov/pubmed/36313371
http://dx.doi.org/10.3389/fphar.2022.991982

Ejemplares similares